4.5 Article

Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1

Journal

MABS
Volume 9, Issue 4, Pages 595-602

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2017.1304341

Keywords

Aggrecanase; cartilage; endocytosis; extracellular matrix; proteoglycanase

Funding

  1. Arthritis Research UK [20563]
  2. Arthritis Research UK Center for Osteoarthritis Pathogenesis [20205]
  3. Cancer Research UK [C100/A8243]
  4. Kennedy Trust for Rheumatology Research
  5. orthopedic Research UK [483]
  6. National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR40994]
  7. Versus Arthritis [20563] Funding Source: researchfish

Ask authors/readers for more resources

The potent aggrecanase ADAMTS-5 is constitutively secreted by chondrocytes, but it is rapidly endocytosed in normal cartilage via the cell surface endocytic receptor LRP1. Therefore it is difficult to detect the total ADAMTS-5 activity produced. In this study, we isolated a monoclonal anti-ADAMTS-5 antibody 1B7 that blocks LRP1-mediated internalization without affecting the aggrecanolytic activity. Addition of 1B7 to cultured human chondrocytes revealed the full aggrecanolytic activity of ADAMTS-5 generated by the cells. 1B7 is a useful tool to estimate the ADAMTS-5 activity and to identify its potential roles in the tissues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available